Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus“ in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
332 Leser
Artikel bewerten:
(1)

AV-Comparatives Tested Consumer and Enterprise Internet Security Solutions for Protection against Advanced and Targeted Attacks

INNSBRUCK, Austria, Nov. 23, 2021 /PRNewswire/ -- AV-Comparatives has released the results of its 2021 Advanced Threat Protection Tests. Eight consumer-antivirus products and eight enterprise endpoint-security programs for Windows were put through their paces.
https://www.av-comparatives.org/testmethod/advanced-threat-protection-tests/

AV-Comparatives state that malware authors continue to write new malicious programs

AV-Comparatives' Advanced Threat Protection Test uses a variety of different attack scenarios, which the tested programs have to defend against. Targeted attacks employ various different techniques to avoid detection by security software. These include fileless attacks, code obfuscation, and the use of legitimate operating-system tools. Disguising malicious code also makes it hard for a security program to recognise. The misuse of legitimate system programs for malicious purposes also makes it easier for cybercriminals to stay under the radar of security measures.

In the Advanced Threat Protection Tests, AV-Comparatives use hacking and penetration techniques that allow attackers to access internal computer systems. These attacks can be broken down into Lockheed Martin's Cybersecurity Kill Chain, and seven distinct phases - each with unique IOCs (Indicators of Compromise) for the victims. All our tests use a subset of the TTP (Tactics, Techniques, Procedures) listed in the MITRE ATT&CK framework. A false alarm test is also included in the reports.

Tested Enterprise Endpoint Security Products include: Acronis Cyber Protect Cloud with Advanced Security Pack; Avast Business Antivirus Pro Plus; Bitdefender Gravity Zone Elite; CrowdStrike Falcon Pro; ESET PROTECT Entry with ESET PROTECT Cloud; G Data Endpoint Protection Business; Kaspersky Endpoint Security for Business - Select with KSC; VIPRE Endpoint Cloud.

All the enterprise products listed above blocked at least eight out of fifteen advanced attacks, and so received AV-Comparatives' ATP Enterprise Certification.

Link to report: https://www.av-comparatives.org/tests/advanced-threat-protection-test-2021-enterprise/

Tested consumer security programs includes: Avast Free Antivirus; AVG Free Antivirus; Bitdefender Internet Security; ESET Internet Security; G Data Total Security; Kaspersky Internet Security; McAfee Total Protection; VIPRE Advanced Security.

Of these, Avast, AVG, ESET, Kaspersky and McAfee consumer products reached the highest ADVANCED+ rating.

Link to report: https://www.av-comparatives.org/tests/advanced-threat-protection-test-2021-consumer/

"The Advanced Threat Protection Test checks each security product's ability to protect a computer against targeted attacks, which are known as "advanced persistent threats" (APTs). These are complex, multi-stage attacks that are aimed at a specific individual or organisation. Whilst the majority of such attacks may be ultimately aimed at infiltrating enterprise networks, an obvious means of doing this is to target the personal computers of staff members within the organisation. Additionally, cybercriminals may launch targeted attacks against individuals for other reasons. This means that protection against such attacks should be provided by consumer security programs, as well as corporate endpoint protection software.", says Peter Stelzhammer, co-founder of AV-Comparatives.

All of the tested products, consumer and enterprise, had to defend against 15 different complex targeted attacks.

AV-Comparatives is an independent organization offering systematic testing that checks whether security software, such as PC/Mac-based antivirus products and mobile security solutions, lives up to its promises. Using one of the largest sample collections worldwide, it creates a real-world environment for truly accurate testing. AV-Comparatives offers freely accessible results to individuals, news organizations and scientific institutions. Certification by AV-Comparatives provides an official seal of approval for software performance which is globally recognized.

Contact: Peter Stelzhammer
e-mail: media@av-comparatives.org
phone: +43 720115542

Photo - https://mma.prnewswire.com/media/1694890/AV_Comparatives_1.jpg
Photo - https://mma.prnewswire.com/media/1694889/AV_Comparatives_2.jpg
Logo - https://mma.prnewswire.com/media/1093032/AV_Comparatives_Logo.jpg

Advanced Threat Protection is more important then ever, for enterprise as well as for consumers.

AV-Comparatives logo

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.